- Home
- RDFN vs SNDX Comparison
RDFN vs SNDX Comparison
Compare RDFN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- SNDX
- Stock Information
- Founded
- RDFN 2002
- SNDX 2005
- Country
- RDFN United States
- SNDX United States
- Employees
- RDFN N/A
- SNDX N/A
- Industry
- RDFN Real Estate
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- SNDX Health Care
- Exchange
- RDFN Nasdaq
- SNDX Nasdaq
- Market Cap
- RDFN 1.1B
- SNDX 1.1B
- IPO Year
- RDFN 2017
- SNDX 2016
- Fundamental
- Price
- RDFN $7.19
- SNDX $12.66
- Analyst Decision
- RDFN Hold
- SNDX Strong Buy
- Analyst Count
- RDFN 11
- SNDX 10
- Target Price
- RDFN $9.43
- SNDX $36.20
- AVG Volume (30 Days)
- RDFN 4.3M
- SNDX 2.9M
- Earning Date
- RDFN 02-25-2025
- SNDX 02-25-2025
- Dividend Yield
- RDFN N/A
- SNDX N/A
- EPS Growth
- RDFN N/A
- SNDX N/A
- EPS
- RDFN N/A
- SNDX N/A
- Revenue
- RDFN $1,016,774,000.00
- SNDX $16,000,000.00
- Revenue This Year
- RDFN $8.63
- SNDX N/A
- Revenue Next Year
- RDFN $9.90
- SNDX N/A
- P/E Ratio
- RDFN N/A
- SNDX N/A
- Revenue Growth
- RDFN 3.70
- SNDX N/A
- 52 Week Low
- RDFN $5.10
- SNDX $12.40
- 52 Week High
- RDFN $15.29
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- RDFN 30.25
- SNDX 36.72
- Support Level
- RDFN $6.96
- SNDX $12.40
- Resistance Level
- RDFN $8.37
- SNDX $14.65
- Average True Range (ATR)
- RDFN 0.41
- SNDX 0.60
- MACD
- RDFN -0.07
- SNDX 0.14
- Stochastic Oscillator
- RDFN 12.41
- SNDX 18.22
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.